Jammbe Musoro comes to the EORTC from his native Cameroon by way of The Netherlands, where he is a doctoral candidate in biostatistics at the University of Amsterdam Academic Medical Center. The topic of his dissertation is “Statistical analysis of repeated outcomes of different types”. In 2015 he was awarded the International Society for Clinical Biostatistics student conference award for his presentation on “Dynamic prediction of recurrent event data by landmarking with application to a follow-up study of patients after kidney transplant.”
At the EORTC Jammbe will be involved in a minimal important difference (MID) project of the EORTC Quality of Life Department under the supervision of Corneel Coens. Determining what represents a MID in health-related quality of life HRQOL scores is useful to clinicians, patients and researchers, and can be used as a benchmark for assessing the success of a health care intervention (e.g., a new treatment). It also has implications for the design of a clinical trial, in particular for establishing sample size and power calculations. More so, it is one of the most frequent requests for information which the EORTC HQ receives at the QOL department from most of the users of the measures, from both academics and industry
The main goal of Jammbe’s research is to empirically evaluate the appropriateness of clinical anchors in establishing MIDs. This will entail, for instance, using advanced statistical methods such as joint modelling to appropriately answer questions like; (i) how does the association between the anchor and HRQOL scores change over time and across different populations, and (ii) how is the evolution of the anchor profile related to the evolution of the HRQOL scores?
Specific goals of his project comprise:
- Exploration and publication of a novel way of statistically evaluating the appropriateness of particular anchors in the determination of MIDs in the anchor-based approach.
- Establish and publish a library of MIDs on the EORTC QLQ-C30 across various patient populations, e.g., across different cancer sites (lung, brain etc.) as well as across stages of the disease.
- The above results will eventually cumulate in an overall guidance on the value, limitations and practical use of MIDs in the design, analysis and interpretation of clinical trials.
- Finally, based on the results obtained, additional empirical investigation of the size and patterns of MIDs across domains of the EORTC QLQ-C30 will be considered where justified.
Jammbe Musoro’s EORTC Fellowship is supported by a grant from the EORTC Quality of Life Group.